| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/322646 |
| P698 | PubMed publication ID | 11565068 |
| P2093 | author name string | F Mandelli | |
| P Ricci | |||
| B Martino | |||
| D D'Antonio | |||
| F Menichetti | |||
| D Russo | |||
| G Gentile | |||
| A Del Favero | |||
| P Martino | |||
| A Micozzi | |||
| G Bucaneve | |||
| Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program | |||
| P Furno | |||
| P2860 | cites work | Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Tre | Q34722117 |
| 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America | Q38556043 | ||
| Amikacin serum concentrations: prediction of levels and dosage guidelines | Q39214222 | ||
| Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group | Q40700791 | ||
| A Comparison of Imipenem to Ceftazidime With or Without Amikacin as Empiric Therapy in Febrile Neutropenic Patients | Q40737330 | ||
| A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia | Q40805848 | ||
| A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients | Q40835219 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| amikacin | Q408529 | ||
| multicenter clinical trial | Q6934595 | ||
| placebo-controlled trial | Q108853737 | ||
| P304 | page(s) | 1295-1301 | |
| P577 | publication date | 2001-09-14 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia | |
| P478 | volume | 33 |
| Q34114674 | 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer |
| Q45305512 | A Comparative Study of Piperacillin-Tazobactam With and Without Vancomycin as Empirical Therapy for Febrile Neutropenic Patients With Solid Tumor Malignancies |
| Q40519085 | A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. |
| Q24246468 | Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients |
| Q34180913 | Aminoglycoside-free interventional antibiotic management in patients undergoing haemopoietic stem cell transplantation |
| Q39024862 | Antibiotic susceptibility of Gram-negatives isolated from bacteremia in children with cancer. Implications for empirical therapy of febrile neutropenia |
| Q38117578 | Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations |
| Q40508848 | Bacteremia in patients with hematological malignancies |
| Q24201767 | Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia |
| Q24248048 | Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia |
| Q40496949 | Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens |
| Q39220949 | Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli |
| Q40346737 | Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy. |
| Q51617424 | Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. |
| Q40321694 | Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia |
| Q36301709 | Converting cancer therapies into cures: lessons from infectious diseases |
| Q43085783 | Drug susceptibility and clonality of methicillin-resistant Staphylococcus epidermidis in hospitalized patients with hematological malignancies |
| Q36093598 | Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial |
| Q36496470 | Empirical antibiotic treatment with piperacillin-tazobactam in patients with microbiologically-documented biliary tract infections. |
| Q24201136 | Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer |
| Q38747206 | Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. |
| Q40503352 | Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. |
| Q40324601 | Evaluation of Bloodstream Infections During Chemotherapy-Induced Febrile Neutropenia in Patients with Malignant Hematological Diseases: Single Center Experience |
| Q35033597 | Evidence-based guidelines for empirical therapy of neutropenic fever in Korea |
| Q53976941 | Infections in neutropenic cancer patients. |
| Q35557446 | Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment |
| Q51151949 | Liver abscess after radiofrequency ablation of tumors in patients with a biliary tract procedure. |
| Q40364811 | Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin/tazobactam, a randomized trial |
| Q40585149 | Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis |
| Q40484723 | Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison |
| Q38620812 | Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients. |
| Q38202573 | Neutropenic fever and sepsis: evaluation and management |
| Q40539790 | Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia |
| Q35901732 | Optimum management of pediatric patients with fever and neutropenia |
| Q37298859 | Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia |
| Q37773368 | Pharmacokinetic evaluation of piperacillin-tazobactam |
| Q40561453 | Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. |
| Q36839703 | Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination |
| Q40275670 | Piperacillin-tazobactum plus amikacin versus ceftazidime plus amikacin as empirical therapy for Fever in neutropenic patients with hematological malignancies |
| Q40419049 | Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies |
| Q44019734 | Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections |
| Q35047852 | The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients |
| Q31024483 | The use of piperacillin/tazobactam (in association with amikacin) in neonatal sepsis: efficacy and safety data |
| Q36607415 | Treatment of Pseudomonas aeruginosa infection in critically ill patients |
| Q50484768 | [Aminoglycosides]. |
| Q79788312 | [Control scale of antibiotic prescriptions in intensive care] |
Search more.